封面
市場調查報告書
商品編碼
1072067

抗發炎藥的全球市場:展望、預測 (2022-2027年)

Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027

出版日期: | 出版商: Arizton Advisory & Intelligence | 英文 326 Pages | 訂單完成後即時交付

價格

全球抗發炎藥的市場規模在預測期間內預計以6.78%的年複合成長率成長。

由於大規模的病患群組對OTC抗發炎藥的購買行動增加,各種發炎性疾病的盛行率上升,發炎性疾病的治療中生技藥品的使用增加等要素促進該市場的成長。

本報告提供全球抗發炎藥的市場調查,市場概要,市場成長的各種影響因素分析,主要趨勢,市場規模的變化、預測,各種區分、各地區的詳細分析,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 調查手法

第2章 調查目的

第3章 調查流程

第4章 調查範圍

第5章 前提條件、註記

第6章 市場概要

第7章 簡介

第8章 市場機會、趨勢

第9章 市場成長的促進因素

第10章 市場成長的阻礙因素

第11章 市場形勢

  • 市場概要
  • 波特的五力分析

第12章 藥物類別

  • 市場概述、成長引擎
  • 市場概要
  • 生技藥品及生物相似藥
  • NSAIDs
  • 類固醇
  • 其他
    • 市場概要
    • 市場規模、預測

第13章 用途

  • 市場概述、成長引擎
  • 市場概要
  • 自體免疫疾病
  • 呼吸疾病
  • 其他
    • 市場概要
    • 市場規模、預測

第14章 給藥途徑

  • 市場概述、成長引擎
  • 市場概要
  • 非口服劑
  • 口服劑
  • 局部劑
  • 吸入劑
    • 市場概要
    • 市場規模、預測

第15章 地區

  • 市場概述、成長引擎
  • 地區概要

第16章 北美

第17章 歐洲

第18章 亞太地區

第19章 南美

第20章 中東、非洲

第21章 競爭情形

  • 競爭概要
  • 市場佔有率分析

第22章 主要企業簡介

  • ABBVIE
  • AMGEN
  • BIOGEN
  • BRISTOL MYERS SQUIBB
  • ELI LILLY & COMPANY
  • F. HOFFMANN-LA ROCHE
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON
  • MERCK & CO
  • NOVARTIS
  • PFIZER

第23章 其他有力供應商

  • ACTIZA PHARMACEUTICAL
  • ALLERGAN
  • ANTIBE THERAPEUTICS
  • AURINIA PHARMACEUTICALS
  • ASTRAZENECA
  • AUROBINDO PHARMA
  • BAYER
  • BIO-THERASOLUTIONS
  • CADILA PHARMACEUTICALS
  • CIPLA
  • CELLTRION
  • CENTURION REMEDIES
  • DR. REDDY'S LABORATORIES
  • EISAI
  • GILEAD SCIENCES
  • GLENMARK PHARMACEUTICALS
  • LUPIN
  • MEDICO REMEDIES
  • REGENERON PHARMACEUTICALS
  • SAMSUNG BIOEPIS
  • SANOFI
  • SUN PHARMACEUTICAL INDUSTRIES
  • SWEDISH ORPHAN BIOVITRUM
  • UCB
  • FUJIFILM KYOWA KIRIN BIOLOGICS

第24章 報告概要

  • 重要點
  • 策略性推薦事項

第25章 定量性摘要

第26章 附錄

Product Code: ARZ220422

The study considers a detailed scenario of the present global anti-inflammatory drugs market and its market dynamics for 2022-2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

The global anti-inflammatory drugs market is expected to grow at a CAGR of 6.78% during 2022-2027

MARKET GROWTH AND OPPORTUNITIES

  • Rising OTC Buying behavior of Anti-inflammatory drugs Among Larger Patient Groups
  • Rising Prevalence of a Broad Range of Inflammatory Diseases
  • Increasing Use of Biologics for Treating Inflammatory Diseases

GLOBAL ANTI-INFLAMMATORY DRUGS MARKET SHARE AND SEGMENTS

  • Based on drug class, biologics and biosimilars is the major contributor in the global anti-inflammatory drugs market, and it is likely to witness high incremental growth of $33.64 billion during the forecast period.
  • The global anti-inflammatory drugs market is highly competitive and fragmented even though the leading companies are constantly consolidating their market position through strategic and high-profile mergers and acquisitions.

Segmentation by Drug Class

  • Biologics & Biosimilars
  • NSAIDs
  • Steroids
  • Others

Segmentation by Application

  • Autoimmune Diseases
  • Respiratory Diseases
  • Others

Segmentation by Route of Administration

  • Parenteral
  • Oral
  • Topical
  • Inhalation

GEOGRAPHICAL ANALYSIS

In 2021, North America was the major revenue contributor and accounted for 41.38% in the global anti-inflammatory drugs market in 2021 and witness the highest incremental growth of $20.88 billion during the forecast period.

Increasing population, the emergence of autoimmune diseases, expansion of demand, increase in pharma and biopharma facilities, and the advent of COVID-19 are major factors to boost the demand for anti-inflammatory drugs in Europe.

Segmentation by Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

VENDOR ANALYSIS

Key Vendors

  • AbbVie
  • Amgen
  • Biogen
  • Bristol Myers Squibb
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Actiza Pharmaceutical
  • Allergan
  • Antibe Therapeutics
  • Aurinia Pharmaceuticals
  • AstraZeneca
  • Aurobindo Pharma
  • Bayer
  • Bio-Thera Solutions
  • Cadila Pharmaceuticals
  • Cipla
  • Celltrion
  • CENTURION REMEDIES
  • Dr. Reddy's Laboratories
  • Eisai
  • Gilead Sciences
  • Glenmark Pharmaceuticals
  • Lupin
  • Medico Remedies
  • Regeneron Pharmaceuticals
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries
  • Swedish Orphan Biovitrum
  • UCB
  • FUJIFILM KYOWA KIRIN BIOLOGICS
  • Teva pharmaceuticals

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
  • 4.4 MARKET SEGMENTATION
    • 4.4.1 MARKET SEGMENTATION BY DRUG CLASS
    • 4.4.2 MARKET SEGMENTATION BY APPLICATION
    • 4.4.3 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
    • 4.4.4 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW
    • 7.1.1 EPIDEMIOLOGY OF INFLAMMATORY DISEASES
    • 7.1.2 TREATMENT OF INFLAMMATORY DISEASES

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES
  • 8.2 SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES
  • 8.3 RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS

9 MARKET GROWTH ENABLERS

  • 9.1 PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS
  • 9.2 RISING PREVALENCE OF INFLAMMATORY DISEASES
  • 9.3 GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES

10 MARKET RESTRAINTS

  • 10.1 PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS
  • 10.2 SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
  • 10.3 PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
    • 11.1.1 MARKET SIZE & FORECAST
    • 11.1.2 INSIGHTS BY GEOGRAPHY
    • 11.1.3 INSIGHTS BY DRUG CLASS
    • 11.1.4 INSIGHTS BY APPLICATION
    • 11.1.5 INSIGHTS BY ROUTE OF ADMINISTRATION
  • 11.2 FIVE FORCES ANALYSIS
    • 11.2.1 THREAT OF NEW ENTRANTS
    • 11.2.2 BARGAINING POWER OF SUPPLIERS
    • 11.2.3 BARGAINING POWER OF BUYERS
    • 11.2.4 THREAT OF SUBSTITUTES
    • 11.2.5 COMPETITIVE RIVALRY

12 DRUG CLASS

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW
  • 12.3 BIOLOGICS & BIOSIMILARS
    • 12.3.1 MARKET OVERVIEW
    • 12.3.2 MARKET SIZE & FORECAST
  • 12.4 NSAIDS
    • 12.4.1 MARKET OVERVIEW
    • 12.4.2 MARKET SIZE & FORECAST
  • 12.5 STEROIDS
    • 12.5.1 MARKET OVERVIEW
    • 12.5.2 MARKET SIZE & FORECAST
  • 12.1 OTHERS
    • 12.1.1 MARKET OVERVIEW
    • 12.1.2 MARKET SIZE & FORECAST

13 APPLICATION

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 AUTOIMMUNE DISEASES
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
  • 13.4 RESPIRATORY DISEASES
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
  • 13.5 OTHERS
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST

14 ROUTE OF ADMINISTRATION

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 PARENTERAL
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
  • 14.4 ORAL
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
  • 14.5 TOPICAL
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST
  • 14.6 INHALATION
    • 14.6.1 MARKET OVERVIEW
    • 14.6.2 MARKET SIZE & FORECAST

15 GEOGRAPHY

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 GEOGRAPHIC OVERVIEW

16 NORTH AMERICA

  • 16.1 MARKET OVERVIEW
  • 16.2 MARKET SIZE & FORECAST
    • 16.2.1 NORTH AMERICA: DRUG CLASS SEGMENTATION
    • 16.2.2 NORTH AMERICA: INDICATION SEGMENTATION
    • 16.2.3 NORTH AMERICA: ROUTE OF ADMINISTERATION SEGMENTATION
  • 16.3 KEY COUNTRIES
    • 16.3.1 US: MARKET SIZE & FORECAST
    • 16.3.2 CANADA: MARKET SIZE & FORECAST

17 EUROPE

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
    • 17.2.1 EUROPE: DRUG CLASS SEGMENTATION
    • 17.2.2 EUROPE: APPLICATION SEGMENTATION
    • 17.2.3 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
  • 17.3 KEY COUNTRIES
    • 17.3.1 GERMANY: MARKET SIZE & FORECAST
    • 17.3.2 THE UK: MARKET SIZE & FORECAST
    • 17.3.3 FRANCE: MARKET SIZE & FORECAST
    • 17.3.4 ITALY: MARKET SIZE & FORECAST
    • 17.3.5 SPAIN: MARKET SIZE & FORECAST

18 APAC

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
    • 18.2.1 APAC: DRUG CLASS SEGMENTATION
    • 18.2.2 APAC: APPLICATION SEGMENTATION
    • 18.2.3 APAC: ROUTE OF ADMINISTERATION SEGMENTATION
  • 18.3 KEY COUNTRIES
    • 18.3.1 CHINA: MARKET SIZE & FORECAST
    • 18.3.2 JAPAN: MARKET SIZE & FORECAST
    • 18.3.3 INDIA: MARKET SIZE & FORECAST
    • 18.3.4 AUSTRALIA: MARKET SIZE & FORECAST
    • 18.3.5 SOUTH KOREA: MARKET SIZE & FORECAST

19 LATIN AMERICA

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 LATIN AMERICA: DRUG CLASS SEGMENTATION
    • 19.2.2 LATIN AMERICA: APPLICATION SEGMENTATION
    • 19.2.3 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
  • 19.3 KEY COUNTRIES
    • 19.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 19.3.2 MEXICO: MARKET SIZE & FORECAST
    • 19.3.3 ARGENTINA : MARKET SIZE & FORECAST

20 MIDDLE EAST AND AFRICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION
    • 20.2.2 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION
    • 20.2.3 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTERATION SEGMENTATION
  • 20.3 KEY COUNTRIES
    • 20.3.1 TURKEY: MARKET SIZE & FORECAST
    • 20.3.2 SOUTH AFRICA: MARKET SIZE & FORECAST
    • 20.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST

21 COMPETITIVE LANDSCAPE

  • 21.1 COMPETITION OVERVIEW
  • 21.2 MARKET SHARE ANALYSIS

22 KEY COMPANIES PROFILES

  • 22.1 ABBVIE
    • 22.1.1 BUSINESS OVERVIEW
    • 22.1.2 PRODUCT OFFERINGS
    • 22.1.3 KEY STRATEGIES
    • 22.1.4 KEY STRENGTHS
    • 22.1.5 KEY OPPORTUNITIES
  • 22.2 AMGEN
    • 22.2.1 BUSINESS OVERVIEW
    • 22.2.2 PRODUCT OFFERINGS
    • 22.2.3 KEY STRATEGIES
    • 22.2.4 KEY STRENGTHS
    • 22.2.5 KEY OPPORTUNITIES
  • 22.3 BIOGEN
    • 22.3.1 BUSINESS OVERVIEW
    • 22.3.2 PRODUCT OFFERINGS
    • 22.3.3 KEY STRATEGIES
    • 22.3.4 KEY STRENGTHS
    • 22.3.5 KEY OPPORTUNITIES
  • 22.4 BRISTOL MYERS SQUIBB
    • 22.4.1 BUSINESS OVERVIEW
    • 22.4.2 PRODUCT OFFERINGS
    • 22.4.3 KEY STRATEGIES
    • 22.4.4 KEY STRENGTHS
    • 22.4.5 KEY OPPORTUNITIES
  • 22.5 ELI LILLY & COMPANY
    • 22.5.1 BUSINESS OVERVIEW
    • 22.5.2 PRODUCT OFFERINGS
    • 22.5.3 KEY STRATEGIES
    • 22.5.4 KEY STRENGTHS
    • 22.5.5 KEY OPPORTUNITIES
  • 22.6 F. HOFFMANN-LA ROCHE
    • 22.6.1 BUSINESS OVERVIEW
    • 22.6.2 PRODUCT OFFERINGS
    • 22.6.3 KEY STRATEGIES
    • 22.6.4 KEY STRENGTHS
    • 22.6.5 KEY OPPORTUNITIES
  • 22.7 GLAXOSMITHKLINE
    • 22.7.1 BUSINESS OVERVIEW
    • 22.7.2 PRODUCT OFFERINGS
    • 22.7.3 KEY STRATEGIES
    • 22.7.4 KEY STRENGTHS
    • 22.7.5 KEY OPPORTUNITIES
  • 22.8 JOHNSON & JOHNSON
    • 22.8.1 BUSINESS OVERVIEW
    • 22.8.2 PRODUCT OFFERINGS
    • 22.8.3 KEY STRATEGIES
    • 22.8.4 KEY STRENGTHS
    • 22.8.5 KEY OPPORTUNITIES
  • 22.9 MERCK & CO
    • 22.9.1 BUSINESS OVERVIEW
    • 22.9.2 PRODUCT OFFERINGS
    • 22.9.3 KEY STRATEGIES
    • 22.9.4 KEY STRENGTHS
    • 22.9.5 KEY OPPORTUNITIES
  • 22.10 NOVARTIS
    • 22.10.1 BUSINESS OVERVIEW
    • 22.10.2 PRODUCT OFFERINGS
    • 22.10.3 KEY STRATEGIES
    • 22.10.4 KEY STRENGTHS
    • 22.10.5 KEY OPPORTUNITIES
  • 22.11 PFIZER
    • 22.11.1 BUSINESS OVERVIEW
    • 22.11.2 PRODUCT OFFERINGS
    • 22.11.3 KEY STRATEGIES
    • 22.11.4 KEY STRENGTHS
    • 22.11.5 KEY OPPORTUNITIES

23 OTHER PROMINENT VENDORS

  • 23.1 ACTIZA PHARMACEUTICAL
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 PRODUCT OFFERINGS
  • 23.2 ALLERGAN
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 PRODUCT OFFERINGS
  • 23.3 ANTIBE THERAPEUTICS
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 PRODUCT OFFERINGS
  • 23.4 AURINIA PHARMACEUTICALS
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 PRODUCT OFFERINGS
  • 23.5 ASTRAZENECA
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 PRODUCT OFFERINGS
  • 23.6 AUROBINDO PHARMA
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 PRODUCT OFFERINGS
  • 23.7 BAYER
    • 23.7.1 BUSINESS OVERVIEW
    • 23.7.2 PRODUCT OFFERINGS
  • 23.8 BIO-THERASOLUTIONS
    • 23.8.1 BUSINESS OVERVIEW
    • 23.8.2 PRODUCT OFFERINGS
  • 23.9 CADILA PHARMACEUTICALS
    • 23.9.1 BUSINESS OVERVIEW
    • 23.9.2 PRODUCT OFFERINGS
  • 23.10 CIPLA
    • 23.10.1 BUSINESS OVERVIEW
    • 23.10.2 PRODUCT OFFERINGS
  • 23.11 CELLTRION
    • 23.11.1 BUSINESS OVERVIEW
    • 23.11.2 PRODUCT OFFERINGS
  • 23.12 CENTURION REMEDIES
    • 23.12.1 BUSINESS OVERVIEW
    • 23.12.2 PRODUCT OFFERINGS
  • 23.13 DR. REDDY'S LABORATORIES
    • 23.13.1 BUSINESS OVERVIEW
    • 23.13.2 PRODUCT OFFERINGS
  • 23.14 EISAI
    • 23.14.1 BUSINESS OVERVIEW
  • 23.15 GILEAD SCIENCES
    • 23.15.1 BUSINESS OVERVIEW
  • 23.16 GLENMARK PHARMACEUTICALS
    • 23.16.1 BUSINESS OVERVIEW
    • 23.16.2 PRODUCT OFFERINGS
  • 23.17 LUPIN
    • 23.17.1 BUSINESS OVERVIEW
    • 23.17.2 PRODUCT OFFERINGS
  • 23.18 MEDICO REMEDIES
    • 23.18.1 BUSINESS OVERVIEW
    • 23.18.2 PRODUCT OFFERINGS
  • 23.19 REGENERON PHARMACEUTICALS
    • 23.19.1 BUSINESS OVERVIEW
    • 23.19.2 PRODUCT OFFERINGS
  • 23.20 SAMSUNG BIOEPIS
    • 23.20.1 BUSINESS OVERVIEW
    • 23.20.2 PRODUCT OFFERINGS
  • 23.21 SANOFI
    • 23.21.1 BUSINESS OVERVIEW
    • 23.21.2 PRODUCT OFFERINGS
  • 23.22 SUN PHARMACEUTICAL INDUSTRIES
    • 23.22.1 BUSINESS OVERVIEW
    • 23.22.2 PRODUCT OFFERINGS
  • 23.23 SWEDISH ORPHAN BIOVITRUM
    • 23.23.1 BUSINESS OVERVIEW
    • 23.23.2 PRODUCT OFFERINGS
  • 23.24 UCB
    • 23.24.1 BUSINESS OVERVIEW
    • 23.24.2 PRODUCT OFFERINGS
  • 23.25 FUJIFILM KYOWA KIRIN BIOLOGICS
    • 23.25.1 BUSINESS OVERVIEW
    • 23.25.2 PRODUCT OFFERINGS

24 REPORT SUMMARY

  • 24.1 KEY TAKEAWAYS
  • 24.2 STRATEGIC RECOMMENDATIONS

25 QUANTITATIVE SUMMARY

  • 25.1 MARKET BY DRUG CLASS
    • 25.1.1 NORTH AMERICA: DRUG CLASS SEGMENTATION
    • 25.1.3 EUROPE: DRUG CLASS SEGMENTATION
    • 25.1.4 APAC: DRUG CLASS SEGMENTATION
    • 25.1.5 LATIN AMERICA: DRUG CLASS SEGMENTATION
    • 25.1.6 MIDDLE EAST & AFRICA: DRUG CLASS SEGMENTATION
  • 25.2 MARKET BY APPLICATION
    • 25.2.1 NORTH AMERICA: APPLICATION SEGMENTATION
    • 25.2.2 EUROPE: APPLICATION SEGMENTATION
    • 25.2.3 APAC: APPLICATION SEGMENTATION
    • 25.2.4 LATIN AMERICA: APPLICATION SEGMENTATION
    • 25.2.5 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION
  • 25.3 MARKET BY ROUTE OF ADMINISTRATION
    • 25.3.1 NORTH AMERICA: ROUTE OF ADMINISTRATION
    • 25.3.2 EUROPE: ROUTE OF ADMINISTRATION
    • 25.3.3 APAC: ROUTE OF ADMINISTRATION
    • 25.3.4 LATIN AMERICA: ROUTE OF ADMINISTRATION
    • 25.3.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION
  • 25.4 MARKET BY GEOGRAPHY
    • 25.5.1 BIOLOGICS & BIOSIMILARS: GEOGRAPHY SEGMENTATION
    • 25.5.2 NSAIDS: GEOGRAPHY SEGMENTATION
    • 25.5.3 STEROIDS: GEOGRAPHY SEGMENTATION
    • 25.5.4 OTHERS: GEOGRAPHY SEGMENTATION
    • 25.5.5 AUTOIMMUNE DISEASES: GEOGRAPHY SEGMENTATION
    • 25.5.6 RESPIRATORY DISEASES: GEOGRAPHY SEGMENTATION
    • 25.5.7 OTHER DISEASES: GEOGRAPHY SEGMENTATION
    • 25.5.8 PARENTERAL: GEOGRAPHY SEGMENTATION
    • 25.5.9 ORAL: GEOGRAPHY SEGMENTATION
    • 25.5.10 TOPICAL: GEOGRAPHY SEGMENTATION
    • 25.5.11 INHALATIONAL: GEOGRAPHY SEGMENTATION

26 APPENDIX

  • 26.1 ABBREVIATIONS

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF GLOBAL ANTI-INFLAMMATORY DRUGS MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 LIST OF MAJOR INFLAMMATORY DISEASES
  • EXHIBIT 4 IMPACT OF PROMISING INVESTIGATIONAL DRUGS IN CLINICAL TRIAL PIPELINES
  • EXHIBIT 5 IMPACT OF SURGE IN AVAILABILITY OF APPROVED BIOSIMILARS TO TREAT INFLAMMATORY DISEASES
  • EXHIBIT 6 IMPACT OF RISE IN COMMERCIALIZATION OF ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 7 IMPACT OF PREFERENCE FOR ANTI-INFLAMMATORY DRUGS AMONG PATIENT GROUPS
  • EXHIBIT 8 IMPACT OF RISING PREVALENCE OF INFLAMMATORY DISEASES
  • EXHIBIT 9 BURDEN STATISTICS FOR DIFFERENT AUTOIMMUNE DISEASES
  • EXHIBIT 10 COPD DISEASE BURDEN STATISTICS
  • EXHIBIT 11 IMPACT OF GROWING USE OF BIOLOGICS TO TREAT INFLAMMATORY DISEASES
  • EXHIBIT 12 IMPACT OF PATENT EXPIRATION OF ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 13 IMPACT OF SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 14 COMMON SIDE-EFFECTS OF ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 15 ADVERSE EFFECTS OF ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 16 IMPACT OF PRODUCT RECALLS DUE TO STRINGENT REGULATORY GUIDELINES
  • EXHIBIT 17 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 18 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY
  • EXHIBIT 19 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS
  • EXHIBIT 20 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION
  • EXHIBIT 21 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
  • EXHIBIT 22 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 23 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 24 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS
  • EXHIBIT 25 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: INCREMENTAL GROWTH
  • EXHIBIT 26 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS: ABSOLUTE GROWTH
  • EXHIBIT 27 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 28 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021-2027 ($ BILLION)
  • EXHIBIT 29 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 30 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021-2027 ($ BILLION)
  • EXHIBIT 31 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 32 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021-2027 ($ BILLION)
  • EXHIBIT 33 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 34 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021-2027 ($ BILLION)
  • EXHIBIT 35 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
  • EXHIBIT 36 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION
  • EXHIBIT 37 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION: INCREMENTAL GROWTH
  • EXHIBIT 38 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 39 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021-2027 ($ BILLION)
  • EXHIBIT 40 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 41 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021-2027 ($BILLION)
  • EXHIBIT 42 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 43 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021-2027 ($ BILLION)
  • EXHIBIT 44 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 45 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
  • EXHIBIT 46 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: INCREMENTAL GROWTH
  • EXHIBIT 47 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION: ABSOLUTE GROWTH
  • EXHIBIT 48 TYPES OF PARENTERAL ROUTES OF ADMINISTRATION
  • EXHIBIT 49 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 50 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 51 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 52 MAJOR ORAL ANTI-INFLAMMATORY DRUGS
  • EXHIBIT 53 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 54 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 55 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 56 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 57 GLOBAL INHALATION ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 58 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 59 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY
  • EXHIBIT 60 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: KEY COUNTRIES ($ BILLION)
  • EXHIBIT 61 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 62 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 63 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES 2021 ($ BILLION)
  • EXHIBIT 64 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 65 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 66 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027
  • EXHIBIT 67 INCREMENTAL GROWTH BY INDICATION 2021 & 2027
  • EXHIBIT 68 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 69 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
  • EXHIBIT 70 US ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 71 CANADA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 72 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
  • EXHIBIT 73 EUROPE ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 74 EUROPE ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 75 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 76 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 77 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 78 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
  • EXHIBIT 79 GERMANY ANTI-INFLAMMATORY DRUGS MARKET 2020-2027 ($BILLION)
  • EXHIBIT 80 UK ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 81 MORTALITY PERCENTAGE ASSOCIATED WITH CHRONIC INFLAMMATORY DISEASES
  • EXHIBIT 82 FRANCE ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 83 ITALY ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 84 SPAIN ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 85 APAC ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
  • EXHIBIT 86 APAC ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 87 APAC ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 88 INCREMENTAL GROWTH BY DRUG CLASS 2021 & 2027
  • EXHIBIT 89 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 90 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 91 INCREMENTAL GROWTH IN APAC 2021 & 2027
  • EXHIBIT 92 CHINA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 93 JAPAN ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 94 INDIA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 95 AUSTRALIA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 96 SOUTH KOREA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 97 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
  • EXHIBIT 98 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 99 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 100 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 101 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
  • EXHIBIT 102 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 103 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
  • EXHIBIT 104 BRAZIL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 105 MEXICO ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 106 ARGENTINA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 107 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: KEY COUNTRIES
  • EXHIBIT 108 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 109 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($BILLION)
  • EXHIBIT 110 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 111 INCREMENTAL GROWTH BY SEGMENT 2021 & 2027
  • EXHIBIT 112 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 113 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
  • EXHIBIT 114 TURKEY ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 115 SOUTH AFRICA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 116 SAUDI ARABIA ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION)
  • EXHIBIT 117 ABBVIE: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 118 ABBVIE: R&D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 119 ABBVIE: REVENUE BY GEOGRAPHY 2018-2020 ($ BILLION)
  • EXHIBIT 120 AMGEN: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 121 AMGEN: R&D EXPENDITURE 2018-2020 ($ MILLION)
  • EXHIBIT 122 BIOGEN: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 123 BIOGEN: REVENUE BY PRODUCT CATEGORIES 2018-2020 ($ MILLION)
  • EXHIBIT 124 BIOGEN: R&D EXPENDITURE 2018-2020 ($ MILLION)
  • EXHIBIT 125 BRISTOL MYERS SQUIBB: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 126 BRISTOL MYERS SQUIBB: R&D EXPENDITURE 2018-2020 ($ MILLION)
  • EXHIBIT 127 BRISTOL MYERS SQUIBB: REVENUE BY GEOGRAPHIC REGION 2020 ($ MILLION)
  • EXHIBIT 128 ELI LILLY & COMPANY: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 129 ELI LILLY & COMPANY: RESEARCH & DEVELOPMENT 2018-2020 ($ BILLION)
  • EXHIBIT 130 ELI LILLY & COMPANY: REVENUE BY GEOGRAPHY 2018-2020 ($ BILLION)
  • EXHIBIT 131 F. HOFFMANN-LA ROCHE: TOTAL REVENUE 2019-2021 ($ BILLION)
  • EXHIBIT 132 F. HOFFMANN-LA ROCHE: R&D EXPENDITURE 2019-2021 ($ BILLION)
  • EXHIBIT 133 GLAXOSMITHKLINE: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 134 GLAXOSMITHKLINE: REVENUE BY BUSINESS SEGMENTS 2018-2020 ($ BILLION)
  • EXHIBIT 135 GLAXOSMITHKLINE: R& D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 136 GLAXOSMITHKLINE: REVENUE BY GEOGRAPHY 2018-2020 ($ BILLION)
  • EXHIBIT 137 JOHNSON & JOHNSON: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 138 MERCK & CO: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 139 MERCK & CO: REVENUE BY SEGMENTS 2018-2020 ($ BILLION)
  • EXHIBIT 140 MERCK & CO: R&D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 141 NOVARTIS: TOTAL REVENUE 2018-2020 ($ MILLION)
  • EXHIBIT 142 NOVARTIS: R&D EXPENDITURE 2018-2020 ($ MILLION)
  • EXHIBIT 143 NOVARTIS: REVENUE BY BUSINESS SEGMENT 2019-2020 ($ MILLION)
  • EXHIBIT 144 NOVARTIS: REVENUE BY GEOGRAPHY 2020 ($ MILLION)
  • EXHIBIT 145 PFIZER: REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 146 PFIZER: R&D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 147 PFIZER: REVENUE BY GEOGRAPHY 2018-2020 ($ BILLION)
  • EXHIBIT 148 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021-2027 ($ BILLION)
  • EXHIBIT 149 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 150 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY BIOLOGICS & BIOSIMILARS 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 151 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 152 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY NSAIDS 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 153 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 154 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY STEROIDS 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 155 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 156 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DRUG CLASSES 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 157 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 158 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY AUTOIMMUNE DISEASES 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 159 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 160 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY RESPIRATORY DISEASES 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 161 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 162 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY OTHER DISEASES 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 163 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 164 GLOBAL PARENTERAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 165 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 166 GLOBAL ORAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 167 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 168 GLOBAL TOPICAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 (%) (GEOGRAPHY)
  • EXHIBIT 169 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 ($ BILLION) (GEOGRAPHY)
  • EXHIBIT 170 GLOBAL INHALATIONAL ANTI-INFLAMMATORY DRUGS MARKET 2021-2027 (%) (GEOGRAPHY)

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 MAJOR PRODUCTS IN MANAGEMENT OF INFLAMMATORY DISEASES
  • TABLE 4 LIST OF MAJOR INVESTIGATIONAL THERAPIES FOR INFLAMMATORY DISEASES
  • TABLE 5 COST-EFFECTIVENESS OF BIOSIMILARS COMPARED WITH ORIGINATOR BIOLOGICS TO TREAT CHRONIC INFLAMMATORY CONDITIONS
  • TABLE 6 LIST OF POTENTIAL & APPROVED BIOSIMILARS FOR INFLAMMATORY DISEASES
  • TABLE 7 LIST OF RECENTLY APPROVED ANTI-INFLAMMATORY DRUGS
  • TABLE 8 TOP GLOBAL OTC ANTI-INFLAMMATORY DRUG BRANDS
  • TABLE 9 ANTI-INFLAMMATORY OFF-PATENT PRODUCTS
  • TABLE 10 PRODUCTS RECALLS IN GLOBAL ANTI-INFLAMMATORY DRUGS MARKET
  • TABLE 11 LIST OF MAJOR BIOLOGICS & BIOSIMILARS APPROVED FOR INFLAMMATORY DISEASES
  • TABLE 12 MAJOR AVAILABLE PRESCRIPTION NSAIDS
  • TABLE 13 COMMON EXAMPLES OF PARENTERAL ANTI-INFLAMMATORY DRUGS
  • TABLE 14 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 15 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 16 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021-2027 ($ BILLION)
  • TABLE 17 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY INDICATION 2021-2027 (%)
  • TABLE 18 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 19 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 20 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 21 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 22 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 23 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 24 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 25 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 26 APPROVED ANTI-INFLAMMATORY DRUGS IN GERMANY
  • TABLE 27 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 28 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 29 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 30 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 31 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 32 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 33 NMPA-APPROVED ANTI-INFLAMMATORY BIOSIMILARS 2019
  • TABLE 34 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 35 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 36 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 37 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)

LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)

  • TABLE 38 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 39 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 40 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 41 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 42 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 43 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 44 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 45 ABBVIE: MAJOR PRODUCT OFFERINGS
  • TABLE 46 AMGEN: MAJOR PRODUCT OFFERINGS
  • TABLE 47 BIOGEN: MAJOR PRODUCT OFFERINGS
  • TABLE 48 BRISTOL MYERS SQUIBB: MAJOR PRODUCT OFFERINGS
  • TABLE 49 ELI LILLY & COMPANY: MAJOR PRODUCT OFFERINGS
  • TABLE 50 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
  • TABLE 51 GLAXOSMITHKLINE: MAJOR PRODUCT OFFERINGS
  • TABLE 52 JOHNSON & JOHNSON: MAJOR PRODUCT OFFERINGS
  • TABLE 53 MERCK & CO: MAJOR PRODUCT OFFERINGS
  • TABLE 54 NOVARTIS: MAJOR PRODUCT OFFERINGS
  • TABLE 55 PFIZER: MAJOR PRODUCT OFFERINGS
  • TABLE 56 ACTIZA PHARMACEUTICAL: MAJOR PRODUCT OFFERINGS
  • TABLE 57 ALLERGAN: MAJOR PRODUCT OFFERINGS
  • TABLE 58 ANTIBE THERAPEUTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 59 AURINIA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 60 ASTRAZENECA: MAJOR PRODUCT OFFERINGS
  • TABLE 61 AUROBINDO PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 62 BAYER: MAJOR PRODUCT OFFERINGS
  • TABLE 63 BIO-THERA SOLUTIONS: MAJOR PRODUCT OFFERINGS
  • TABLE 64 CADILA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 65 CIPLA: MAJOR PRODUCT OFFERINGS
  • TABLE 66 CELLTRION: MAJOR PRODUCT OFFERINGS
  • TABLE 67 CENTURION REMEDIES: MAJOR PRODUCT OFFERINGS
  • TABLE 68 DR. REDDY'S LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 69 EISAI: MAJOR PRODUCT OFFERINGS
  • TABLE 70 GILEAD SCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 71 GLENMARK PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 72 LUPIN: MAJOR PRODUCT OFFERINGS
  • TABLE 73 MEDICO REMEDIES: MAJOR PRODUCT OFFERINGS
  • TABLE 74 REGENERON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 75 SAMSUNG BIOEPIS: MAJOR PRODUCT OFFERINGS
  • TABLE 76 SANOFI: MAJOR PRODUCT OFFERINGS
  • TABLE 77 SUN PHARMACEUTICAL INDUSTRIES: MAJOR PRODUCT OFFERINGS
  • TABLE 78 SWEDISH ORPHAN BIOVITRUM: MAJOR PRODUCT OFFERINGS
  • TABLE 79 UCB: MAJOR PRODUCT OFFERINGS
  • TABLE 80 FUJIFILM KYOWA KIRIN BIOLOGICS: MAJOR PRODUCT OFFERINGS
  • TABLE 81 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 82 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 83 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 84 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 85 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 86 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 87 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 88 APAC ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 89 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 90 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 91 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 ($ BILLION)
  • TABLE 92 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY DRUG CLASS 2021-2027 (%)
  • TABLE 93 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 94 GLOBAL AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 95 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 96 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 97 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 98 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 99 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 100 APAC ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 101 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 102 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 103 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 ($ BILLION)
  • TABLE 104 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY APPLICATION 2021-2027 (%)
  • TABLE 105 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 106 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 107 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 108 NORTH AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 109 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 110 EUROPE ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 111 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 112 APAC ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 113 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 114 LATIN AMERICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 115 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ BILLION)
  • TABLE 116 MIDDLE EAST & AFRICA ANTI-INFLAMMATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 117 GLOBAL ANTI-INFLAMMATORY DRUGS MARKET BY GEOGRAPHY 2021-2027 (%)